Switch to:
Also traded in: Germany

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 5/10

vs
industry
vs
history
Cash-to-Debt No Debt
CUR's Cash-to-Debt is ranked higher than
88% of the 1018 Companies
in the Global Biotechnology industry.

( Industry Median: 51.38 vs. CUR: No Debt )
Ranked among companies with meaningful Cash-to-Debt only.
CUR' s Cash-to-Debt Range Over the Past 10 Years
Min: 1.09  Med: 244.43 Max: No Debt
Current: No Debt
Equity-to-Asset 0.71
CUR's Equity-to-Asset is ranked lower than
60% of the 744 Companies
in the Global Biotechnology industry.

( Industry Median: 0.67 vs. CUR: 0.71 )
Ranked among companies with meaningful Equity-to-Asset only.
CUR' s Equity-to-Asset Range Over the Past 10 Years
Min: -0.81  Med: 0.61 Max: 0.93
Current: 0.71
-0.81
0.93
Piotroski F-Score: 4
Altman Z-Score: -18.27
Beneish M-Score: -2.41
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 2/10

vs
industry
vs
history
Operating Margin % -92722.22
CUR's Operating Margin % is ranked lower than
99% of the 777 Companies
in the Global Biotechnology industry.

( Industry Median: -119.18 vs. CUR: -92722.22 )
Ranked among companies with meaningful Operating Margin % only.
CUR' s Operating Margin % Range Over the Past 10 Years
Min: -191570  Med: -7353.85 Max: -2071.62
Current: -92722.22
-191570
-2071.62
Net Margin % -98588.89
CUR's Net Margin % is ranked lower than
99% of the 777 Companies
in the Global Biotechnology industry.

( Industry Median: -105.77 vs. CUR: -98588.89 )
Ranked among companies with meaningful Net Margin % only.
CUR' s Net Margin % Range Over the Past 10 Years
Min: -209040  Med: -10615.44 Max: -2017.65
Current: -98588.89
-209040
-2017.65
ROE % -242.54
CUR's ROE % is ranked lower than
96% of the 936 Companies
in the Global Biotechnology industry.

( Industry Median: -38.72 vs. CUR: -242.54 )
Ranked among companies with meaningful ROE % only.
CUR' s ROE % Range Over the Past 10 Years
Min: -1295.32  Med: -234.5 Max: -147.69
Current: -242.54
-1295.32
-147.69
ROA % -111.98
CUR's ROA % is ranked lower than
92% of the 1025 Companies
in the Global Biotechnology industry.

( Industry Median: -33.51 vs. CUR: -111.98 )
Ranked among companies with meaningful ROA % only.
CUR' s ROA % Range Over the Past 10 Years
Min: -270.44  Med: -149.27 Max: -91.88
Current: -111.98
-270.44
-91.88
ROC (Joel Greenblatt) % -6992.77
CUR's ROC (Joel Greenblatt) % is ranked lower than
85% of the 988 Companies
in the Global Biotechnology industry.

( Industry Median: -411.81 vs. CUR: -6992.77 )
Ranked among companies with meaningful ROC (Joel Greenblatt) % only.
CUR' s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: -7999.13  Med: -6997.6 Max: -3877.01
Current: -6992.77
-7999.13
-3877.01
3-Year Revenue Growth Rate -53.60
CUR's 3-Year Revenue Growth Rate is ranked lower than
85% of the 589 Companies
in the Global Biotechnology industry.

( Industry Median: 3.80 vs. CUR: -53.60 )
Ranked among companies with meaningful 3-Year Revenue Growth Rate only.
CUR' s 3-Year Revenue Growth Rate Range Over the Past 10 Years
Min: 0  Med: -73.6 Max: 16.9
Current: -53.6
0
16.9
3-Year EBITDA Growth Rate -10.50
CUR's 3-Year EBITDA Growth Rate is ranked lower than
66% of the 704 Companies
in the Global Biotechnology industry.

( Industry Median: 1.90 vs. CUR: -10.50 )
Ranked among companies with meaningful 3-Year EBITDA Growth Rate only.
CUR' s 3-Year EBITDA Growth Rate Range Over the Past 10 Years
Min: -17.4  Med: -6.25 Max: 36.1
Current: -10.5
-17.4
36.1
3-Year EPS without NRI Growth Rate -10.30
CUR's 3-Year EPS without NRI Growth Rate is ranked lower than
62% of the 684 Companies
in the Global Biotechnology industry.

( Industry Median: -1.40 vs. CUR: -10.30 )
Ranked among companies with meaningful 3-Year EPS without NRI Growth Rate only.
CUR' s 3-Year EPS without NRI Growth Rate Range Over the Past 10 Years
Min: -37.9  Med: -5.15 Max: 32.2
Current: -10.3
-37.9
32.2
GuruFocus has detected 2 Warning Signs with Neuralstem Inc CUR.
More than 500,000 people have already joined GuruFocus to track the stocks they follow and exchange investment ideas.
» CUR's 30-Y Financials

Financials (Next Earnings Date: 2018-02-08 Est.)


Revenue & Net Income
Cash & Debt
Operating Cash Flow & Free Cash Flow
Operating Cash Flow & Net Income

» Details

Guru Trades

CUR Guru Trades in

CUR Guru Trades in

Q2 2015

CUR Guru Trades in Q2 2015

George Soros 18,000 sh (New)
» More
Q3 2015

CUR Guru Trades in Q3 2015

George Soros Sold Out
» More
» Details

Insider Trades

Latest Guru Trades with CUR

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Biotechnology » Biotechnology    NAICS: 325414    SIC: 2836
Compare:NAS:CYCC, NAS:EYEG, NAS:ANTH, NAS:ABIO, NAS:DMPI, TSXV:ARCH, XTAE:TRPX, TSE:2176, BOM:524412, OTCPK:PKTX, BOM:532384, OTCPK:CELZ, ASX:CDY, TSXV:SBM, NAS:CLSN, OTCPK:BIVI, AMEX:OGEN, ASX:BTC, OSTO:CLBIO, LSE:OXP » details
Traded in other countries:7NS1.Germany,
Headquarter Location:USA
Neuralstem Inc is a biotechnology company. It is engaged in the development and commercialization of treatments for central nervous system disease based on transplanting human neural stem cells and the use of small molecule drugs.

Neuralstem Inc is a biotechnology company. It is engaged in the development and commercialization of treatments for central nervous system disease based on transplanting human neural stem cells and the use of small molecule drugs.

Top Ranked Articles about Neuralstem Inc

Neuralstem Announces Presentation of Clinical Data for NSI-189 in Major Depressive Disorder at the Upcoming American College of Neuropsychopharmacology Annual Meeting
Neuralstem Strengthens Executive Leadership Team with Appointment of Dr. David Recker as Chief Medical Officer
Neuralstem Announces the Appointment of Two New Members to the Board of Directors
Neuralstem Announces Issuance of Two U.S. Patents
Neuralstem Awarded $~1MM Grant by NIH to Continue Preclinical Research into the Potential of NSI-189 for Treatment of Diabetic Neuropathy
Neuralstem Announces Pricing of Public Offering of Common Stock and Warrants
Neuralstem Announces Proposed Public Offering of Common Stock and Warrants
Neuralstem Announces Top-line Phase 2 Data of NSI-189 for Major Depressive Disorder
Neuralstem Expands Phase 1 Safety Trial of NSI-566 Neural Stem Cells in Spinal Injury
Neuralstem Reports Year End 2016 Fiscal Results and Business Update
Expects to Report NSI-189 Phase 2 major depressive disorder study results in Q3 ahead of scheduleGERMANTOWN, Md., March 23, 2017 (GLOBE NEWSWIRE) -- Neuralstem, Inc. (NASDAQ:CUR), a biopharmaceutical company focused on the development of nervous system therapies based on its neural stem cell technology, reported its financial results for the fourth quarter and year ended December 31, 2016.“We are pleased with the execution over the past year that includes securing a strategic investment, beating guided clinical timelines and providing additional transparency to the markets,” commented Rich Daly, Chairman and CEO. “Fiscal 2017 is poised to be another strong year for Neuralstem as we approach our largest milestone to date, the results of our Phase 2 major depressive disorder (MDD) clinical study in the third quarter.  We are committed to continuing to explore NSI-189 mechanism of action (MOA) and potential therapeutic benefits in additional indications.”Clinical HighlightsNSI-189 Phase 2 MDD results expected 4 months ahead of schedule in 3Q17.  Neuralstem’s Phase 2 clinical study evaluating NSI-189 for the indication of MDD was initiated in May 2016. The company announced 50% enrollment in September 2016 and last patient enrolled in February 2017. 220 subjects were randomized for a 12-week interventional study with NSI-189 or placebo followed by another 24 weeks of non-interventional observation-only study.

NSI-189 preclinical data suggest pro-cognitive potential. Treatment of mouse brain slices with NSI-189 produced a time- and concentration-dependent enhancement in short-term (STP) and long-term potentiation (LTP), an in vitro model of memory. NSI-189 treatment of brain slices from a mouse model of Angelman Syndrome, a maternally inherited human condition that causes neurologic impairments including cognitive deficits, was able to restore LTP to normal levels. Furthermore, NSI-189 treatment of rats in a radiation-induced brain injury model also ameliorated cognitive impairment and preserved hippocampal neurogenesis.

NSI-189 preclinical data is suggestive of the potential for broader application in nervous system diseases. Data obtained from studies using a rodent model of ischemic stroke demonstrate that NSI-189 can reverse stroke-induced motor and neurological deficits, and that this may involve upregulation of neurotrophic or neurogenic factors. In addition, NSI-189 proved to be effective in the prevention and reversal of peripheral neuropathies in a mouse model of Type 1 diabetes and in the prevention of peripheral neuropathies in a mouse model of Type 2 diabetes. Data from these studies included reversal of neuropathic pain and decreased nerve conductance due to diabetes.Corporate HighlightsStrategic investment of $20 million.  In December 2016, Neuralstem closed a strategic transaction with Tianjin Pharmaceutical Group International Holdings Co., LTD.’s (TJPH or Tianjin) whereby Tianjin purchased $20 million of our securities. The transaction was announced on September 12, 2016.

Rich Daly appointed CEO.  In February 2016, Rich Daly was appointed President and Chief Executive Officer of Neuralstem.  Subsequently in June 2016, he was appointed Chairman of the Board of Directors.  Mr. Daly has over 25 years of pharmaceutical expertise including executive leadership roles at Takeda, AstraZeneca, Bristol-Myers Squibb and Abbott.  He serves on the board of directors of Synergy Pharmaceuticals and Catalyst Pharmaceuticals.

1-for-13 reverse stock split. In January 2017, the Company executed a 1-for-13 reverse stock split of the Company’s common stock. The reverse stock split enabled Neuralstem to regain compliance with the $1.00 minimum bid price condition and thereby fulfill all of the NASDAQ Capital Market continued listing requirements.Financial Results for the Year Ended December 31, 2016Cash Position: Cash, cash equivalents and short-term investments on hand was approximately $20.2 million at December 31, 2016, compared to approximately $12.2 million at December 31, 2015.  The increase resulted from cash raised of approximately $28.1 million, net primarily from our financings in May and December 2016, partially offset by use of cash to fund our NSI-189 clinical programs and to meet our debt repayment obligations. As of December 31, 2016 we had approximately $3.8 million of debt outstanding as compared to $8.3 million at December 31, 2015.Net Loss: In the year ended December 31, 2016, we reported a net loss of approximately $21.1 million or $2.53 per share on a split-adjusted basis, compared to a loss of approximately $20.9 million or $2.99 per share in the year ended December 31, 2015. Our operating loss in the year ended December 31, 2016 was approximately $20.6 million, compared to a loss of approximately $19.2 million in the year ended December 31, 2015.R&D Expenses: Research and development expenditures, at $13.2 million, increased by approximately $0.5 million in 2016 as compared to expenditures of $12.6 million in 2015. The increase in research and development expenses was primarily attributable to severance payments made as a result of our reduction in force in May together with an increase in bonus accrual year over year, partially offset by a reduction in ongoing payroll costs.G&A Expenses: General and administrative expenses increased by approximately $1.0 million dollars to $7.4 million in the year ended December 31, 2016 as compared to $6.5 million for the year ended December 31, 2015. The increase was primarily attributable to an increase in legal and professional fees associated with company financing activities, product licensing and Nasdaq compliance efforts, and to severance payments made as a result of our reduction in force in May together with an increase in bonus accrual year over year, partially offset by a reduction in ongoing payroll costs.Equity and Reverse Stock Split: The Board of Directors approved a 1-for-13 reverse stock split of the Company’s common stock effective January 6, 2017.  Stockholders' equity and all references to share and per share amounts in the accompanying consolidated financial statements have been retroactively adjusted to reflect the 1-for-13 reverse stock split for all periods presented.We had 11.0 million and 7.1 million common shares issued and outstanding on a reverse split adjusted basis and 1.0 million and 0 preferred shares issued and outstanding at December 31, 2016 and 2015, respectively.Liquidity: We expect that our existing cash, cash equivalents and short-term investments will fund our anticipated level of operations based on our current operating plans, into the second quarter of 2018.Neuralstem, Inc. Consolidated Balance Sheets  December 31,  2016 2015     ASSETS        CURRENT ASSETS        Cash and cash equivalents $15,194,949  $4,716,533 Short-term investments  5,000,000   7,517,453 Trade and other receivables  10,491   37,316 Current portion of related party receivable, net of discount  53,081   - Prepaid expenses  646,195   1,159,782 Total current assets  20,904,716   13,431,084          Property and equipment, net  269,557   343,200 Patents, net  990,153   1,103,467 Related party receivable, net of discount and current portion  424,240   - Other assets  15,662   71,797 Total assets $22,604,328  $14,949,548          LIABILITIES AND STOCKHOLDERS' EQUITY        CURRENT LIABILITIES        Accounts payable and accrued expenses $2,343,936  $1,455,826 Accrued bonuses  852,963   161,362 Current portion of long-term debt, net of fees and discount  3,705,787   4,545,180 Other current liabilities  430,738   263,104 Total current liabilities  7,333,424   6,425,472          Long-term debt, net of fees, discount and current portion  -   3,382,654 Derivative instruments  3,921,917   - Other long term liabilities  18,209   174,144 Total liabilities  11,273,550   9,982,270          STOCKHOLDERS' EQUITY        Preferred stock, 7,000,000 shares authorized, $0.01 par value; 1,000,000 and 0 shares issued and outstanding at December 31, 2016 and 2015, respectively  10,000   - Common stock, $0.01 par value; 300 million shares authorized, 11,032,858 and 7,077,362 shares issued and outstanding in 2016 and 2015, respectively  110,329   70,774 Additional paid-in capital  204,239,837   176,852,115 Accumulated other comprehensive income  3,905   3,071 Accumulated deficit  (193,033,293)  (171,958,682)Total stockholders' equity  11,330,778   4,967,278 Total liabilities and stockholders' equity $22,604,328  $14,949,548          
Neuralstem, Inc. Consolidated Statements of Operations and Comprehensive Loss   Year Ended December 31,  2016 2015     Revenues $16,246  $10,417          Operating expenses:        Research and development costs  13,155,887   12,637,278 General and administrative expenses  7,497,202   6,529,667 Total operating expenses  20,653,089   19,166,945 Operating loss  (20,636,843)  (19,156,528)         Other income (expense):        Interest income  58,835   69,549 Interest expense  (1,141,297)  (1,816,206)Gain on related party settlement  458,608   - Gain from change in fair value of derivative instruments  660,253   - Fees related to issuance of derivative instruments and other expenses  (474,167)  (716)Total other income (expense)  (437,768)  (1,747,373)         Net loss $(21,074,611) $(20,903,901)         Net loss per common share - basic and diluted $(2.53) $(2.99)         Weighted average common shares outstanding - basic and diluted  8,345,992   6,989,764          Comprehensive loss:        Net loss $(21,074,611) $(20,903,901)Foreign currency translation adjustment  834   (2,929)Comprehensive loss $(21,073,777) $(20,906,830)         About NeuralstemNeuralstem’s patented technology enables the commercial-scale production of multiple types of central nervous system stem cells, which are being developed as potential therapies for multiple central nervous system (CNS) diseases and conditions.Neuralstem’s technology enables the discovery of small molecule compounds by systematic screening of chemical compounds against its proprietary human hippocampal stem cell line.  The screening process has led to the discovery and patenting of molecules that Neuralstem believes may stimulate the brain’s capacity to generate new neurons, potentially reversing pathophysiologies associated with certain central and peripheral nervous system conditions.The company has completed Phase 1a and 1b studies evaluating NSI-189, a novel neurogenic small molecule product candidate, for the treatment of major depressive disorder or MDD, and is currently conducting a Phase 2 efficacy study for MDD.Neuralstem’s stem cell therapy product candidate, NSI-566, is a spinal cord-derived neural stem cell line. Neuralstem is currently evaluating NSI-566 in three indications: stroke, chronic spinal cord injury (cSCI), and Amyotrophic Lateral Sclerosis (ALS).Neuralstem is conducting a Phase 1 safety study for the treatment of paralysis from chronic motor stroke at the BaYi Brain Hospital in Beijing, China.  In addition, NSI-566 was evaluated in a Phase 1 safety study to treat paralysis due to chronic spinal cord injury as well as a Phase 1 and Phase 2a risk escalation, safety trials for ALS.  Subjects from all three indications are currently in long-term observational follow-up periods and continued to be monitored for safety and possible therapeutic benefits.Cautionary Statement Regarding Forward Looking InformationThis news release contains “forward-looking statements” made pursuant to the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements relate to future, not past, events and may often be identified by words such as “expect,” “anticipate,” “intend,” “plan,” “believe,” “seek” or “will.” Forward-looking statements by their nature address matters that are, to different degrees, uncertain. Specific risks and uncertainties that could cause our actual results to differ materially from those expressed in our forward-looking statements include risks inherent in the development and commercialization of potential products, uncertainty of clinical trial results or regulatory approvals or clearances, need for future capital, dependence upon collaborators and maintenance of our intellectual property rights. Actual results may differ materially from the results anticipated in these forward-looking statements. Additional information on potential factors that could affect our results and other risks and uncertainties are detailed from time to time in Neuralstem’s periodic reports, including the Annual Report on Form 10-K for the year ended December 31, 2016, filed with the Securities and Exchange Commission (SEC) on March 23, 2017, and in other reports filed with the SEC. We do not assume any obligation to update any forward-looking statements.
Contact:
Neuralstem – Investor Relations:
Danielle Spangler
301.366.1481

Lori Rosen
Public Relations
LDR Communications
917.553.6808

Read more...

Ratios

vs
industry
vs
history
PB Ratio 1.39
CUR's PB Ratio is ranked higher than
77% of the 923 Companies
in the Global Biotechnology industry.

( Industry Median: 4.10 vs. CUR: 1.39 )
Ranked among companies with meaningful PB Ratio only.
CUR' s PB Ratio Range Over the Past 10 Years
Min: 1.39  Med: 11.24 Max: 59.51
Current: 1.39
1.39
59.51
EV-to-EBIT -0.12
CUR's EV-to-EBIT is ranked lower than
99.99% of the 253 Companies
in the Global Biotechnology industry.

( Industry Median: 23.72 vs. CUR: -0.12 )
Ranked among companies with meaningful EV-to-EBIT only.
CUR' s EV-to-EBIT Range Over the Past 10 Years
Min: -26.9  Med: -5.7 Max: -0.1
Current: -0.12
-26.9
-0.1
EV-to-EBITDA -0.12
CUR's EV-to-EBITDA is ranked lower than
99.99% of the 280 Companies
in the Global Biotechnology industry.

( Industry Median: 19.29 vs. CUR: -0.12 )
Ranked among companies with meaningful EV-to-EBITDA only.
CUR' s EV-to-EBITDA Range Over the Past 10 Years
Min: -27.3  Med: -5.8 Max: -0.1
Current: -0.12
-27.3
-0.1
EV-to-Revenue 111.17
CUR's EV-to-Revenue is ranked lower than
91% of the 752 Companies
in the Global Biotechnology industry.

( Industry Median: 12.83 vs. CUR: 111.17 )
Ranked among companies with meaningful EV-to-Revenue only.
CUR' s EV-to-Revenue Range Over the Past 10 Years
Min: 34.9  Med: 846.75 Max: 26339.7
Current: 111.17
34.9
26339.7
Current Ratio 8.01
CUR's Current Ratio is ranked higher than
57% of the 1008 Companies
in the Global Biotechnology industry.

( Industry Median: 4.13 vs. CUR: 8.01 )
Ranked among companies with meaningful Current Ratio only.
CUR' s Current Ratio Range Over the Past 10 Years
Min: 0.52  Med: 3.98 Max: 16.97
Current: 8.01
0.52
16.97
Quick Ratio 8.01
CUR's Quick Ratio is ranked higher than
59% of the 1007 Companies
in the Global Biotechnology industry.

( Industry Median: 3.83 vs. CUR: 8.01 )
Ranked among companies with meaningful Quick Ratio only.
CUR' s Quick Ratio Range Over the Past 10 Years
Min: 0.52  Med: 3.98 Max: 16.97
Current: 8.01
0.52
16.97
Days Sales Outstanding 1.00
CUR's Days Sales Outstanding is ranked lower than
73% of the 631 Companies
in the Global Biotechnology industry.

( Industry Median: 67.34 vs. CUR: 1.00 )
Ranked among companies with meaningful Days Sales Outstanding only.
CUR' s Days Sales Outstanding Range Over the Past 10 Years
Min: 1  Med: 784.47 Max: 4341.58
Current: 1
1
4341.58

Buy Back

vs
industry
vs
history
3-Year Average Share Buyback Ratio -22.60
CUR's 3-Year Average Share Buyback Ratio is ranked lower than
65% of the 742 Companies
in the Global Biotechnology industry.

( Industry Median: -13.20 vs. CUR: -22.60 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
CUR' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -24.1  Med: -15.3 Max: -7.1
Current: -22.6
-24.1
-7.1

Valuation & Return

vs
industry
vs
history
Price-to-Net-Cash 1.71
CUR's Price-to-Net-Cash is ranked higher than
85% of the 543 Companies
in the Global Biotechnology industry.

( Industry Median: 7.30 vs. CUR: 1.71 )
Ranked among companies with meaningful Price-to-Net-Cash only.
CUR' s Price-to-Net-Cash Range Over the Past 10 Years
Min: 1.71  Med: 15.21 Max: 60.94
Current: 1.71
1.71
60.94
Price-to-Net-Current-Asset-Value 1.61
CUR's Price-to-Net-Current-Asset-Value is ranked higher than
85% of the 684 Companies
in the Global Biotechnology industry.

( Industry Median: 7.12 vs. CUR: 1.61 )
Ranked among companies with meaningful Price-to-Net-Current-Asset-Value only.
CUR' s Price-to-Net-Current-Asset-Value Range Over the Past 10 Years
Min: 1.61  Med: 14.86 Max: 78.44
Current: 1.61
1.61
78.44
Price-to-Tangible-Book 1.51
CUR's Price-to-Tangible-Book is ranked higher than
78% of the 841 Companies
in the Global Biotechnology industry.

( Industry Median: 5.09 vs. CUR: 1.51 )
Ranked among companies with meaningful Price-to-Tangible-Book only.
CUR' s Price-to-Tangible-Book Range Over the Past 10 Years
Min: 1.51  Med: 14.43 Max: 56.44
Current: 1.51
1.51
56.44
Price-to-Median-PS-Value 0.96
CUR's Price-to-Median-PS-Value is ranked lower than
65% of the 619 Companies
in the Global Biotechnology industry.

( Industry Median: 0.98 vs. CUR: 0.96 )
Ranked among companies with meaningful Price-to-Median-PS-Value only.
CUR' s Price-to-Median-PS-Value Range Over the Past 10 Years
Min: 0.07  Med: 0.31 Max: 14.42
Current: 0.96
0.07
14.42
Earnings Yield (Greenblatt) % -833.33
CUR's Earnings Yield (Greenblatt) % is ranked lower than
98% of the 1021 Companies
in the Global Biotechnology industry.

( Industry Median: -7.65 vs. CUR: -833.33 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) % only.
CUR' s Earnings Yield (Greenblatt) % Range Over the Past 10 Years
Min: -1814.6  Med: -17.4 Max: -3.7
Current: -833.33
-1814.6
-3.7

More Statistics

Revenue (TTM) (Mil) $0.02
EPS (TTM) $ -1.82
Beta0.75
Short Percentage of Float6.87%
52-Week Range $0.88 - 6.60
Shares Outstanding (Mil)15.15

Analyst Estimate

Dec17 Dec18 Dec19
Revenue (Mil $)
EPS ($) -0.18 -0.21 -0.22
EPS without NRI ($) -0.18 -0.21 -0.22
EPS Growth Rate
(Future 3Y To 5Y Estimate)
N/A
Dividends per Share ($)

Piotroski F-Score Details

Piotroski F-Score: 44
Positive ROAN
Positive CFROAN
Higher ROA yoyN
CFROA > ROAY
Lower Leverage yoyY
Higher Current Ratio yoyY
Less Shares Outstanding yoyN
Higher Gross Margin yoyN
Higher Asset Turnover yoyY

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)

GF Chat

{{numOfNotice}}